How VX-407 affects birth control pills in women, studied for polycystic kidney disease
Tests how VX-407 changes the way the body handles oral contraceptives.
Plain-language title generated from the registry record
Registry title: Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT07792408, who can take part
Where in Canada
- Altasciences - Beaumont Clinic MontrealMontreal, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Trial code
- NCT07792408
- Record updated
- 30 September 2026
- Original description
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.Read full original descriptionShow less
A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives
The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.
Inclusion: Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m\^2), inclusive; A total body weight of greater than (>) 50 kg.
Exclusion: History of febrile illness within 5 days before the first dose of study drug; Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug; Other protocol defined Inclusion/Exclusion criteria will apply.